ARMP AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
ARMP Current Performance
-3.00%
Armata pharmaceuticals inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ARMP
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
UPC | Universe pharmaceuticals inc | 1 | 5 | 2 | - | 1 | |
URGN | Urogen pharma ltd | 3 | 4 | 3 | 3 | 1 | |
MURA | Mural oncology plc | - | 3 | 2 | - | 1 | |
ANRO | Alto neuroscience inc | - | 3 | 2 | 3 | 1 | |
GUTS | Fractyl health inc | - | 2 | 2 | 2 | 1 |
- UPC Universe pharmaceuticals incValue 1Trend 5Swing Trading 2Whale Interest -Dividend 1See more
ARMP Profile
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.